GLEN ALLEN, Va., July 7, 2022 /CNW/ -- Glaucoma, one of the world's leading causes of irreversible blindness, is expected to affect an estimated 120 million by 2040, globally. Treatment options for ...

BENGALURU, India, Oct. 10, 2019 /PRNewswire/ -- Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and EU. In many countries, less than 10% of patients ...

Diagnosing eye diseases requires bulky machines and specialist clinics, which are often concentrated in large cities. But for millions living in smaller towns and rural regions, access to timely eye ...

World's first Smartphone based offline AI expands geographical scope to deliver convenience and increase access to DR screening. BANGALORE, India, Feb. 23, 2023 /CNW/ -- Remidio has received CE mark ...

Bengaluru-based health-tech firm to test whether retinal imaging can help detect pregnancy complications in India and African ...

GLEN ALLEN, Va., May 7, 2024 /PRNewswire/ -- Remidio Inc., a health technology innovator developing cutting-edge technology to combat global blindness from Diabetic Retinopathy, Glaucoma, AMD, & ...

Bengaluru: Medtech startup Remidio has unveiled Neubo 130, an AI-powered retinal imaging device designed to diagnose neonatal retinal conditions such as Retinopathy of Prematurity (ROP). The Neubo 130 ...

New Delhi: In a move set to redefine non-invasive disease detection, Remidio, a global leader in AI-powered ophthalmic solutions, has invested in Occuity, a UK-based developer of handheld, optical ...

Bengaluru-based Remidio Innovative Solutions has received a grant from the Gates Foundation to advance its Oculomics platform, which uses retinal imaging and AI to detect signs of systemic disease, ...

Bangalore (Karnataka) [India], February 23 (ANI/PRNewswire): Remidio has received CE mark approval for its Medios AI, to detect Referable DR. This approval closely follows the nod the AI received from ...